Mutations in the Protein Kinase-Binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a Are Associated with Treatment Response

An interaction of the hepatitis C virus (HCV) NS5A protein with the interferon (IFN)-α-inducible double-stranded RNA-activated protein kinase (PKR) was demonstrated in vitro. The clinical correlation between amino acid mutations within the HCV NS5A region and response to antiviral treatment is controversial. Thirty-two patients chronically infected with HCV-1a, who were treated with IFN-α with or without ribavirin, were studied. The carboxy-terminal half of HCV NS5A was sequenced and was investigated by phylogenetic and conformational analyses. Eight patients achieved a sustained virologic response. An end-of-treatment response but relapse thereafter was observed among 8 patients, whereas 16 patients were nonresponders. The median number of mutations within the PKR-binding domain but not within the previously described IFN sensitivity-determining region was significantly higher for patients with sustained (3 mutations [range, 1–5]) or end-of-treatment (4 mutations [range, 1–5]) virologie response than for nonresponders (2 mutations [range, 0–3]) (P = .0087). Phylogenetic and conformational analyses of NS5A sequences allowed no differentiation between sensitive and resistant strains.